[HTML][HTML] Epigenetic dysregulation in chronic myeloid leukaemia: A myriad of mechanisms and therapeutic options
S Koschmieder, D Vetrie - Seminars in cancer biology, 2018 - Elsevier
The onset of global epigenetic changes in chromatin that drive tumor proliferation and
heterogeneity is a hallmark of many forms of cancer. Identifying the epigenetic mechanisms …
heterogeneity is a hallmark of many forms of cancer. Identifying the epigenetic mechanisms …
HDAC inhibitors: Promising agents for leukemia treatment
Y Deng, Q Cheng, J He - Biochemical and Biophysical Research …, 2023 - Elsevier
The essential role of epigenetic modification in the pathogenesis of a series of cancers have
gradually been recognized. Histone deacetylase (HDACs), as well-known epigenetic …
gradually been recognized. Histone deacetylase (HDACs), as well-known epigenetic …
Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T‐cell lymphoma
L Marquard, LM Gjerdrum, IJ Christensen… - …, 2008 - Wiley Online Library
Aims: Aberrant histone acetylation has been associated with malignancy and histone
deacetylase (HDAC) inhibitors are currently being investigated in numerous clinical trials …
deacetylase (HDAC) inhibitors are currently being investigated in numerous clinical trials …
I13 overrides resistance mediated by the T315I mutation in chronic myeloid leukemia by direct BCR-ABL inhibition
C Gao, L Zhang, Y Xu, X Ma, P Chen… - Frontiers in …, 2023 - frontiersin.org
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by a BCR-ABL
fusion gene. Imatinib has significantly improved the treatment of CML as a first-generation …
fusion gene. Imatinib has significantly improved the treatment of CML as a first-generation …
The contributory roles of histone deacetylases (HDACs) in hematopoiesis regulation and possibilities for pharmacologic interventions in hematologic malignancies
M Mehrpouri, A Pourbagheri-Sigaroodi… - International …, 2021 - Elsevier
Although the definitive role of epigenetic modulations in a wide range of hematologic
malignancies, spanning from leukemia to lymphoma and multiple myeloma, has been …
malignancies, spanning from leukemia to lymphoma and multiple myeloma, has been …
Epigenetic reprogramming and emerging epigenetic therapies in CML
J Bugler, R Kinstrie, MT Scott, D Vetrie - Frontiers in Cell and …, 2019 - frontiersin.org
Chronic myeloid leukemia (CML) is a hematopoietic stem cell disorder characterized by
BCR-ABL1, an oncogenic fusion gene arising from the Philadelphia chromosome. The …
BCR-ABL1, an oncogenic fusion gene arising from the Philadelphia chromosome. The …
14‐3‐3 ligand prevents nuclear import of c‐ABL protein in chronic myeloid leukemia
M Mancini, N Veljkovic, V Corradi, E Zuffa, P Corrado… - Traffic, 2009 - Wiley Online Library
Here we demonstrated that the 'loss of function'of not‐rearranged c‐ABL in chronic myeloid
leukemia (CML) is promoted by its cytoplasmic compartmentalization bound to 14‐3‐3 …
leukemia (CML) is promoted by its cytoplasmic compartmentalization bound to 14‐3‐3 …
β-Arrestin1 promotes the progression of chronic myeloid leukaemia by regulating BCR/ABL H4 acetylation
R Qin, K Li, X Qi, X Zhou, L Wang, P Zhang… - British journal of …, 2014 - nature.com
Background: β-Arrestins are scaffold proteins that interact with various cellular signals.
Although β-arrestin2 mediates the initiation and progression of myeloid leukaemia, the …
Although β-arrestin2 mediates the initiation and progression of myeloid leukaemia, the …
[HTML][HTML] Different BCR/Abl protein suppression patterns as a converging trait of chronic myeloid leukemia cell adaptation to energy restriction
S Bono, M Lulli, VG D'Agostino, F Di Gesualdo… - Oncotarget, 2016 - ncbi.nlm.nih.gov
BCR/Abl protein drives the onset and progression of Chronic Myeloid Leukemia (CML). We
previously showed that BCR/Abl protein is suppressed in low oxygen, where viable cells …
previously showed that BCR/Abl protein is suppressed in low oxygen, where viable cells …
mTOR inhibitor RAD001 (Everolimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-ABL protein
M Mancini, V Corradi, S Petta, G Martinelli, E Barbieri… - Leukemia research, 2010 - Elsevier
Constitutive tyrosine kinase (TK) activity of p210 BCR-ABL fusion protein of chronic myeloid
leukemia (CML) usurps physiological functions of normal p145 c-ABL protein. Accordingly …
leukemia (CML) usurps physiological functions of normal p145 c-ABL protein. Accordingly …